New Delhi | November 29, 2013 22:02 (IST)
Rejecting the proposal by the Commerce and Industry Ministry, the Cabinet has decided not to lower the FDI limit for existing pharmaceutical firms.
November 29, 2013 11:27 (IST)
The company says the current total market size for the drug is $59 million per year, citing estimates by healthcare information provider IMS Health, and says it expects to launch this product in the fourth quarter of fiscal 2013-14.
New Delhi | November 28, 2013 22:33 (IST)
The abbreviated new drug applications (ANDAs) approval from the US Food and Drug Administration is for Quetiapine Fumarate tablet, generic version AstraZeneca's Seroquel is in strength of 25 mg (base).
New Delhi | November 27, 2013 16:42 (IST)
The Cabinet is likely to take a decision on relaxing foreign direct investment (FDI) norms for the housing sector and reducing foreign investment limit to 49 per cent in rare and critical areas of the pharma segment on Thursday, according to an official source.
New Delhi | November 26, 2013 17:44 (IST)
Biocon Ltd said on Tuesday it has won approval from the Drug Controller General of India (DGCA) for marketing a generic version of Roche's Herceptin, used in breast cancer treatment.
New Delhi | November 26, 2013 16:41 (IST)
Sources said the proposal is aimed at clarifying the level of overseas investment in the sensitive sector. It was earlier felt that foreign institutional investment (FII) could be over and above the FDI limit of 49 per cent.
Mumbai | November 25, 2013 16:02 (IST)
It also wants to expand beyond its core U.S., Indian and Japanese markets into Latin America, Eastern Europe and China, and is prepared to spend as much as $1 billion to buy brands and companies in coming years.
Reported By: Sandeep Phukan | November 23, 2013 00:21 (IST)
The UPA government may be trying its best to attract foreign direct investment (FDI) but there is, at least, one sector where the government wants to bring it down.
New Delhi | November 22, 2013 19:45 (IST)
It has also proposed to incorporate conditions for foreign firms like mandatory investment in R&D and non-compete clause in the shareholders pact.
New Delhi | November 22, 2013 01:47 (IST)
Homegrown drug maker Cadila Pharmaceuticals on Thursday launched a new lung cancer drug, Mycidac-C, priced at Rs 40,000 for a 10-course injection, about a tenth of the cost of those made by multinational competitors.
Mumbai | November 20, 2013 21:59 (IST)
In the international market, Pfizer completed its acquisition of Wyeth in 2009. However, the Indian arms of both the companies remained two separately listed entities on the domestic stock exchanges, Pfizer said in a statement here.
London | November 19, 2013 22:29 (IST)
GlaxoSmithKline said on Tuesday that it planned to reduce its investment in South African drug maker Aspen Pharmacare by one third, although it would retain a board seat and a significant shareholding.
New Delhi | November 18, 2013 23:53 (IST)
Foreign direct investment (FDI) in the pharmaceutical sector has more than doubled to $1.07 billion during the period between April and August amid concerns over increasing acquisitions of domestic firms by multinationals. FDI in drugs was at $487 million during the corresponding period last year, according to latest data from the Department of Industrial Policy and Promotion (DIPP).
Mumbai | November 15, 2013 00:43 (IST)
Global pharmaceutical major GlaxoSmithKline (GSK) on Thursday announced a Rs 864 crore investment in India to set up a medicine manufacturing unit.
New Delhi | November 14, 2013 16:50 (IST)
The Department of Industrial Policy and Promotion (DIPP) has proposed these steps in its draft cabinet note for tightening foreign direct investment (FDI) in the existing domestic pharmaceutical companies.
New Delhi | November 06, 2013 23:45 (IST)
Drug major Wockhardt said on Wednesday that it will take a revenue hit of nearly one million pounds due to import restrictions imposed by the Medicine and Healthcare Products Regulatory Agency, UK on medicines made at its Kadaiya facility in Nani Daman.
Mumbai | October 25, 2013 16:51 (IST)
The average estimate for the company's net profit was Rs 240 crore, according to a Reuters poll of two brokerages.
October 22, 2013 22:42 (IST)
The factory will however be allowed to test, make and supply to Britain certain drugs critical to public health, the statement to the stock exchanges said Tuesday.
Mumbai | October 17, 2013 20:44 (IST)
Healthcare providers in India are expected to spend $1 billion on IT products and services in 2013, an increase of 7 per cent over 2012, according to research firm Gartner.
New Delhi | October 17, 2013 20:42 (IST)
The Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday initiated recall of five prescription medicines of India's Wockhardt, following manufacturing deficiencies identified during an inspection of the company's site in Chikalthana in Maharashtra.